{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:08:52Z","timestamp":1785845332428,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T00:00:00Z","timestamp":1232668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s15010-008-8128-6","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T05:08:57Z","timestamp":1232687337000},"page":"358-364","source":"Crossref","is-referenced-by-count":32,"title":["Biomarkers of Thrombosis, Fibrinolysis, and Inflammation in Patients with Severe Sepsis due to Community-Acquired Pneumonia with and without Streptococcus pneumoniae"],"prefix":"10.1007","volume":"37","author":[{"given":"G. M.","family":"Vail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. J.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Haney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,1,23]]},"reference":[{"key":"8128_CR1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jinf.2005.10.010","volume":"53","author":"P. Ylipalosaari","year":"2006","unstructured":"Ylipalosaari P, la-Kokko TI, Laurila J, Ohtonen P, Syrjala H: Community- and hospital-acquired infections necessitating ICU admission: spectrum, co-morbidities and outcome. J Infect 2006; 53: 85\u201392.","journal-title":"J Infect"},{"key":"8128_CR2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0025-7125(05)70388-6","volume":"85","author":"T. Neuhaus","year":"2001","unstructured":"Neuhaus T, Ewig S: Defining severe community-acquired pneumonia. Med Clin North Am 2001; 85: 1413\u20131425.","journal-title":"Med Clin North Am"},{"key":"8128_CR3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.1996.03530260048030","volume":"275","author":"M.J. Fine","year":"1996","unstructured":"Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN: Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134\u2013141.","journal-title":"JAMA"},{"key":"8128_CR4","unstructured":"Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46: 1\u201324."},{"key":"8128_CR5","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00001432-200112000-00007","volume":"14","author":"M.I. Restrepo","year":"2001","unstructured":"Restrepo MI, Jorgensen JH, Mortensen EM, Anzueto A: Severe community-acquired pneumonia: current outcomes, epidemiology, etiology, and therapy. Curr Opin Infect Dis 2001; 14: 703\u2013709.","journal-title":"Curr Opin Infect Dis"},{"key":"8128_CR6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1517\/14656566.8.5.593","volume":"8","author":"L. Pineda","year":"2007","unstructured":"Pineda L, El Solh AA: Severe community-acquired pneumonia: approach to therapy. Expert Opin Pharmacother 2007; 8: 593\u2013606.","journal-title":"Expert Opin Pharmacother"},{"key":"8128_CR7","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/cc2459","volume":"8","author":"G.T. Kinasewitz","year":"2004","unstructured":"Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF: Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism (ISRCTN74215569). Crit Care 2004; 8: R82\u2013R90.","journal-title":"Crit Care"},{"key":"8128_CR8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/CDLI.10.5.813-820.2003","volume":"10","author":"S. Fernandez-Serrano","year":"2003","unstructured":"Fernandez-Serrano S, Dorca J, Coromines M, Carratala J, Gudiol F, Manresa F: Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 2003; 10: 813\u2013820.","journal-title":"Clin Diagn Lab Immunol"},{"key":"8128_CR9","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/archinte.167.15.1655","volume":"167","author":"J.A. Kellum","year":"2007","unstructured":"Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC: Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) study. Arch Intern Med 2007; 167: 1655\u20131663.","journal-title":"Arch Intern Med"},{"key":"8128_CR10","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1128\/IAI.70.8.4226-4238.2002","volume":"70","author":"E. Wang","year":"2002","unstructured":"Wang E, Simard M, Ouellet N, Bergeron Y, Beauchamp D, Bergeron MG: Pathogenesis of pneumococcal pneumonia in cyclophosphamide-induced leukopenia in mice. Infect Immun 2002; 70: 4226\u20134238.","journal-title":"Infect Immun"},{"key":"8128_CR11","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1182\/blood-2002-05-1380","volume":"103","author":"A.W. Rijneveld","year":"2004","unstructured":"Rijneveld AW, Weijer S, Florquin S, Esmon CT, Meijers JC, Speelman P, Reitsma PH, Ten CH, van der Poll T: Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 2004; 103: 1702\u20131709.","journal-title":"Blood"},{"key":"8128_CR12","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/01.CCM.0000218807.20570.C2","volume":"34","author":"A.W. Rijneveld","year":"2006","unstructured":"Rijneveld AW, Weijer S, Bresser P, Florquin S, Vlasuk GP, Rote WE, Spek CA, Reitsma PH, van der Zee JS, Levi M, van der Poll T: Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34: 1725\u20131730.","journal-title":"Crit Care Med"},{"key":"8128_CR13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/01.CCM.0000162381.24074.D7","volume":"33","author":"P.F. Laterre","year":"2005","unstructured":"Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF: Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33: 952\u2013961.","journal-title":"Crit Care Med"},{"key":"8128_CR14","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"L.A. Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG: Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27\u2013S72.","journal-title":"Clin Infect Dis"},{"key":"8128_CR15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","volume":"344","author":"G.R. Bernard","year":"2001","unstructured":"Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699\u2013709.","journal-title":"N Engl J Med"},{"key":"8128_CR16","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1097\/01.CCM.0000085089.88077.AF","volume":"31","author":"J.F. Dhainaut","year":"2003","unstructured":"Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D: The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med 2003; 31: 2291\u20132301.","journal-title":"Crit Care Med"},{"key":"8128_CR17","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00134-003-1731-1","volume":"29","author":"J.F. Dhainaut","year":"2003","unstructured":"Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003; 29: 894\u2013903.","journal-title":"Intensive Care Med"},{"key":"8128_CR18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00003246-200301000-00002","volume":"31","author":"E.W. Ely","year":"2003","unstructured":"Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31: 12\u201319.","journal-title":"Crit Care Med"},{"key":"8128_CR19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1160\/TH02-11-0270","volume":"90","author":"J.F. Dhainaut","year":"2003","unstructured":"Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G III, Kinasewitz GT: Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90: 642\u2013653.","journal-title":"Thromb Haemost"},{"key":"8128_CR20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2307\/2531052","volume":"42","author":"J. Robins","year":"1986","unstructured":"Robins J, Breslow N, Greenland S: Estimators of the Mantel-Haenszel variance consistent in both sparse data and largestrata limiting models. Biometrics 1986; 42: 311\u2013323.","journal-title":"Biometrics"},{"key":"8128_CR21","doi-asserted-by":"crossref","first-page":"R92","DOI":"10.1186\/cc4946","volume":"10","author":"A.F. Shorr","year":"2006","unstructured":"Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, Sundin DP: Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 2006; 10: R92.","journal-title":"Crit Care"},{"key":"8128_CR22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1164\/ajrccm.160.3.9901107","volume":"160","author":"M. Ruiz","year":"1999","unstructured":"Ruiz M, Ewig S, Torres A, Arancibia F, Marco F, Mensa J, Sanchez M, Martinez JA: Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160: 923\u2013929.","journal-title":"Am J Respir Crit Care Med"},{"key":"8128_CR23","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0140-6736(03)15021-0","volume":"362","author":"T.M. File","year":"2003","unstructured":"File TM: Community-acquired pneumonia. Lancet 2003; 362: 1991\u20132001.","journal-title":"Lancet"},{"key":"8128_CR24","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/01.CCM.0000218807.20570.C2","volume":"34","author":"A.W. Rijneveld","year":"2006","unstructured":"Rijneveld AW, Weijer S, Bresser P, Florquin S, Vlasuk GP, Rote WE, Spek CA, Reitsma PH, van der Zee JS, Levi M, van der Poll T: Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34: 1725\u20131730.","journal-title":"Crit Care Med"},{"key":"8128_CR25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1183\/09031936.04.00119503","volume":"24","author":"F. Paganin","year":"2004","unstructured":"Paganin F, Lilienthal F, Bourdin A, Lugagne N, Tixier F, Genin R, Yvin JL: Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004; 24: 779\u2013785.","journal-title":"Eur Respir J"},{"key":"8128_CR26","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1378\/chest.121.4.1262","volume":"121","author":"A.F. Shorr","year":"2002","unstructured":"Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS: D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 2002; 121: 1262\u20131268.","journal-title":"Chest"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-008-8128-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-008-8128-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-008-8128-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:27:14Z","timestamp":1589502434000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-008-8128-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,23]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["8128"],"URL":"https:\/\/doi.org\/10.1007\/s15010-008-8128-6","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,23]]}}}